Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study

Lipids in Health and Disease

Golakoti Trimurtulu⁴  Alluri V Krishnaraju⁴  Kadainti VS Sarma¹  Manikeswar K Rao³  Atmatrana T Mishra²  Krishanu Sengupta⁴ 

[1]Department of Statistics, SV University, Tirupati, India

[2]Department of Internal Medicine, ASR Academy of Medical Sciences, Eluru, India

[3]Suraksha Health Village, Gurunanak Nagar, Vijayawada, India

[4]Laila Impex R&D Center, Unit-I, Phase-III, J. Autonagar, Vijayawada, India

关键词: Preadipocyte factor 1;    Obesity;    LI85008F;    Clinical trial;    Adipromin;    Adiponectin;   

Others  :  1160196
DOI  :  10.1186/1476-511X-11-122

 received in 2012-08-01, accepted in 2012-09-05,  发布年份 2012

【 摘 要 】

Background

The effect of an herbal formulation LI85008F on weight loss in obese human subjects was evaluated in an 8-weeks randomized, double-blind, placebo-controlled study (Clinical Trial Registration no. ISRCTN37381706). Fifty obese subjects (Body mass index 30 to 40 kg/m², 29.3% male; 70.7% female; ages 27–50 years) were randomized into two groups; placebo (n = 25) and LI85008F formulation (n = 25). The participants received either 900 mg/day of LI85008F formulation in three divided doses or three identical placebo capsules and all of them remained on a calorie-controlled diet (2000 cal/day) and 30 min walking for 5 days a week during the entire duration of the study.

Results and discussion

At the end of the trial period, LI85008F supplemented group showed significant net reductions in body weight and Body Mass Index (BMI). The participants who received the herbal formulation, showed reduced fasting blood glucose, LDL, LDL/HDL ratio, and triglycerides. At the end of the study, LI85008F supplementation also provided 21.26% (p = 0.012) increase in serum adiponectin level, compared with the placebo group. No major adverse events were reported by the participants in the study duration. In addition, Adipokine profiling study in 3T3-L1 adipocytes demonstrates that LI85008F modulates key regulatory factors of adipogenic differentiation and insulin sensitivity, such as Adiponectin, Pref-1, and resistin.

Conclusion

The herbal formulation LI85008F (Adipromin) is prepared from commonly used medicinal plants extracts, which provides useful and safe application for weight loss in obese humans. It also demonstrates potential promise in controlling healthy blood glucose level in obesity linked type 2 diabetes.

【 授权许可】

   
2012 Sengupta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Faust IM, Johnson PR, Stern JS, Hirsch J: Diet-induced adipocytes number increase in adult rats: a new model of obesity. Am J Physiol 1978, 235:E279-E286.
• [2]Klyde BJ, Hirsch J: Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J Lipid Res 1979, 20:705-715.
• [3]Klyde BJ, Hirsch J: Isotopic labeling of DNA in rat adipose tissue: evidence for proliferating cells associated with mature adipocytes. J Lipid Res 1979, 20:691-704.
• [4]Obesity the global epidemic http://www.iaso.org/iotf/obesity/obesitytheglobalepidemic/ webcite
• [5]Mallare JT, Karabell AH, Velasquez-Mieyer P, Stender SRS, Christensen ML: Current and future treatment of metabolic syndrome and type 2 diabetes in children and adolescents. Diabetes Spectrum 2005, 18:220-228.
• [6]Daniels S: Pharmacological treatment of obesity in pediatric patients. Pediatr Drugs 2000, 13:405-410.
• [7]Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, Robinson TN, Scott BJ, Jeor SS, Williams CL: Overweight in children and adolescents: pathophysiology, consequences, prevention and treatment. Circulation 2005, 111:1999-2012.
• [8]Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G: Primary pulmonary hypertension and fenfluramine use. British Heart Journal 1993, 70:537-541.
• [9]Sengupta K, Golakoti T, Chirravuri VR, Marasetti AK: An herbal formula LI85008F inhibits lipogenesis in 3T3-L1 adipocytes. Food and Nutrition Sciences 2011, 2:809-817.
• [10]Krishnaraju AV, Sundararaju D, Srinivas P, Rao CV, Sengupta K, Trimurtulu G: Safety and toxicological evaluation of a novel anti-obesity formulation LI85008F in animals. Toxicol Mech Methods 2010, 20:59-68.
• [11]Power analysis for ANOVA designs http://www.math.yorku.cal/SCS/Online/power/ webcite
• [12]Preuss HG, Bagchi D, Bagchi M, Rao CVS, Dey DK, Satyanarayana S: Effects of natural extract of (−)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obesity and Metabolism 2004, 6:171-180.
• [13]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
• [14]Haluzik M, Parizkova J, Haluzik MM: Adiponectin and its role in the obesity induced insulin resistance and related complications. Physiol Res 2004, 53:123-129.
• [15]Díez JJ, Iglesias P: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148:293-300.
• [16]Wang Y, Kim KA, Kim JH, Sul HS: Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr 2006, 136:2953-2956.
• [17]Moon YS, Smas CM, Lee K, Villena JA, Kim KH, Yun EJ, Sul HS: Mice lacking paternally expressed Pref-1/Dlk1 display growth retardation and accelerated adiposity. Mol Cell Biol 2002, 22:5585-5592.
• [18]Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
• [19]Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288:H2031-H2041.
• [20]Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N: Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999, 70:1040-1045.
• [21]Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995, 333:276-282.
• [22]Oben J, Kuate D, Agbor G, Momo C, Talla X: The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis 2006, 5:24. BioMed Central Full Text
• [23]Paek KW, Hong YM: Health behavior factors affecting waist circumference as an indicator of abdominal obesity. J Prev Med Pub Health 2006, 39:59-66.
• [24]Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R: Visceral fat is an independent predictor of all-cause mortality in men. Obesity 2006, 14:336-341.
• [25]Ukkola O, Santaniemi M: Adiponectin: a link between excess adiposity and associated comorbidities. J Mol Med 2002, 80:696-702.
• [26]Statnick MA, Breavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000, 1:81-88.
• [27]Kannel WB: Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5:167-173.
• [28]Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.